At Prevail Therapeutics, we are developing novel gene therapies that target the root genetic causes of Parkinson’s disease and other neurodegenerative disorders. Our mission is to translate recent advances in human genetics and gene therapy technology into medicines that slow or stop the neurodegenerative process. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders.
Prevail was formed in 2017 and we are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City.
Prevail Therapeutics was acquired by Eli Lilly and Company in January of 2021, and is now a wholly owned subsidiary of Eli Lilly. For information please visit the www.lilly.com website.
Prevail was formed in 2017 and we are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City.
Prevail Therapeutics was acquired by Eli Lilly and Company in January of 2021, and is now a wholly owned subsidiary of Eli Lilly. For information please visit the www.lilly.com website.
Location: United States, New York
Employees: 51-200
Total raised: $125M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | Omega Fund... | omegafunds... |
| - | RA Capital... | racap.com |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.03.2019 | Series B | $50M | - |
| 08.03.2018 | Series A | $75M | - |
Mentions in press and media 11
| Date | Title | Description |
| 11.09.2020 | GSK and J&J alum Vijay Reddy to take control of R&D at Tmunity; Andrew Hirsch exits Agios for CEO job at C4 Therapeutics | Vijay Reddy → Vijay Reddy was seeking a return to the US when he left his role as CMO at London-based Autolus this summer. Philadelphia is that landing spot, as the T cell immunotherapy player Tmunity has put him in charge... |
| 28.03.2019 | Daily funding roundup - March 28th, 2019 | BillionToOne raised $15M; Polyneuron Pharmaceuticals secured $22.6M;Prevail Therapeutics lands $50M Artiphon: Artiphon is empowering a new generation to explore music-making with smart instruments and adaptive software. Artiphon has raised ... |
| 28.03.2019 | Prevail Therapeutics Secures $50M in Series B Financing | Prevail Therapeutics, Inc., a New York, NY-based gene therapy company developing Adeno-Associated Virus-based gene therapies for patients with devastating neurodegenerative diseases, raised $50m in Series B financing. Backers included: – ex... |
| 27.03.2019 | Prevail Therapeutics raises $50M for gene therapy in Parkinson’s, other neurodegenerative disorders | According to its website, the company’s focus is on developing adeno-associated viral vector-based gene therapies for diseases like Parkinson’s disease. Its hypothesis is that by restoring healthy lysosomal function to the cells of a patien... |
| 27.03.2019 | Prevail Therapeutics Secures $50 Million in Series B | NEW YORK--(BUSINESS WIRE)--Prevail Therapeutics Inc. (Prevail), a gene therapy company developing AAV-based gene therapies for patients with devastating neurodegenerative diseases, today announced it has raised $50 million in Series B finan... |
| 17.03.2019 | Prevail Therapeutics Secures $50 Million in Series B Financing to Advance Pipeline of Gene Therapies for Neurodegenerative Diseases | - |
| 08.03.2018 | Prevail Therapeutics Announces $75 Million Series A | NEW YORK--(BUSINESS WIRE)--Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, today announced a $75 million Series A financing.... |
| 08.03.2018 | Prevail Therapeutics Nabs $75M | NEW YORK, NY, Prevail Therapeutics today announced a $75 million Series A financing. >> Click here for more funding data on Prevail Therapeutics >> To export Prevail Therapeutics funding data to PDF and Excel, click here ... |
| 08.03.2018 | Prevail Therapeutics Raises $75M in Series A Financing | Prevail Therapeutics, Inc., a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, raised $75m in Series A financing. Backers included OrbiMed, Pontifax Fund, RA Capital... |
| 08.03.2018 | Prevail Therapeutics Announces $75 Million Series A | NEW YORK--(BUSINESS WIRE)--Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, today announced a $75 million Series A financing.... |
Show more